New drug cocktail targets tough pancreatic cancer
NCT ID NCT04820179
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of two drugs, atezolizumab and cabozantinib, in 30 people with metastatic pancreatic cancer that has not responded to standard treatments. The goal is to see if the combination can shrink tumors or stop them from growing. Researchers will also monitor side effects and study immune changes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- atezolizumab and cabozantinib
- What this could lead to
- If it works, this could offer a new treatment option for people with advanced pancreatic cancer that has stopped responding to standard chemotherapy.
- What could go wrong
- This is a small, early-phase trial with only 30 participants. The combination may not shrink tumors or improve survival, and side effects could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Arizona Cancer Center
Tucson, Arizona, 85724, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- MRI might reveal hidden pancreatic risks in obesity
- Can a new PET tracer light up hidden cancers?